While patients with high-risk prostate cancer should receive prompt treatment, data suggest that patients and urologists need not rush others into treatment.
Cleveland Clinic researchers have outlined how resistance to enzalutamide treatment develops in advanced prostate cancer, and now have evidence about how to reverse it.
Increasing data implicate diet — particularly elevated dairy and meat intake and high glycemic load — as a contributing factor in prostate cancer incidence and aggressiveness. Cleveland Clinic hopes to impact prostate cell biology by an intensive dietary manipulation and supplement program for men with prostate cancer.
How well do functional medicine treatments help asthma patients? Cleveland Clinic’s Center for Functional Medicine is conducting research alongside experts from the Respiratory Institute to find out. This is one of a handful of studies underway at Cleveland Clinic to gather evidence-based data on functional medicine treatments.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic is now a participant in the American Urological Association’s Quality Registry (AQUA), a national urologic disease registry that measures and reports healthcare quality and patient outcomes. Howard Goldman, MD, the Glickman Urological & Kidney Institute’s Vice Chairman for Quality, explains how the AQUA registry works, and how taking part benefits physicians and patients.
Genomic testing is increasingly impacting prostate cancer diagnosis and treatment, helping clinicians make more informed management decisions based on the specific molecular characteristics of an individual patient’s cancer. In a video interview, Eric A. Klein, MD, Chairman of Cleveland Clinic’s Glickman Urological & Kidney Institute, discusses the broadening use of molecular-based tests.
Glickman Urological & Kidney Institute Chairman Eric Klein, MD, discusses advanced prostate cancer screening tests and prognostic tools developed at Cleveland Clinic and elsewhere that should help reduce unnecessary biopsies and allow clinicians to focus on high-risk patients.
Prostate cancer patients with an inherited gene mutation that enables intratumoral androgen synthesis are highly likely to develop resistance to androgen deprivation therapy and to die years earlier of their disease, researchers from Cleveland Clinic and Mayo Clinic have found. A screening test based on the mutation could inform clinical care.
Rather than abandoning routine prostate-specific antigen-based prostate cancer screening – a move that may have contributed to a recent rise in metastatic cancers – the right approach is to strategically use PSA and other diagnostic tools, says Glickman Urological & Kidney Institute Chairman Eric Klein, MD.
Cleveland Clinic Glickman Urological & Kidney Institute Chairman Eric Klein, MD, describes efforts to expand genomic testing to stratify good and bad outcomes in men with intermediate- and high-risk early-stage prostate cancer, and discusses advantages and challenges of the tests.